Jump to Main Content
Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals
- Vass, Panna, Démuth, Balázs, Hirsch, Edit, Nagy, Brigitta, Andersen, Sune K., Vigh, Tamás, Verreck, Geert, Csontos, István, Nagy, Zsombor K., Marosi, György
- Journal of controlled release 2019 v.296 pp. 162-178
- bioavailability, biopharmaceuticals, drug formulations, drying, immune response, inflammatory bowel disease, intestines, manufacturing, oral administration, patient compliance, toxicity
- In chronic intestinal diseases like inflammatory bowel disease, parenteral administration of biopharmaceuticals is associated with numerous disadvantages including immune reactions, infections, low patient compliance, and toxicity caused by high systemic bioavailability. One alternative that can potentially overcome these limitations is oral administration of biopharmaceuticals, where the local delivery will reduce the systemic exposure and furthermore the manufacturing costs will be lower. However, the development of oral dosage forms that deliver the biologically active form to the intestines is one of the greatest challenges for pharmaceutical technologists due to the sensitive nature of biopharmaceuticals.The present article discusses the various drug delivery technologies used to produce orally administered solid dosage forms of biopharmaceuticals with an emphasis on colon-targeted delivery. Solid oral dosage compositions containing different types of colon-targeting biopharmaceuticals are compiled followed by a review of currently applied and emerging drying technologies for biopharmaceuticals. The different drying technologies are compared in terms of their advantages, limitations, costs and their effect on product stability.